Year-Long trial tests psychedelic Drug's staying power against PTSD
NCT ID NCT06237426
Summary
This study followed 44 people with PTSD for a full year to see if treatment with the drug methylone (TSND-201) provides lasting relief. Participants were monitored monthly for their PTSD symptoms and safety. If their symptoms returned during the year, they could be eligible to receive another course of the methylone treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST TRAUMATIC STRESS DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, England, United Kingdom
-
Cedar Clinical Research, Inc
Draper, Utah, 84020, United States
-
Clerkenwell Health
London, United Kingdom
-
Kings College
London, United Kingdom
-
La Nua Mental Health Centre
Galway, Ireland
-
Mirabilis Health
Belfast, Northern Ireland, United Kingdom
-
Mountain View Clinical Research
Denver, Colorado, 80209, United States
-
NHS Greater Glasgow and Clyde
Glasgow, Scotland, United Kingdom
-
Sunstone Medical
Rockville, Maryland, 20850, United States
Conditions
Explore the condition pages connected to this study.